Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma - 05/12/20
Doi : 10.1016/j.jaad.2020.08.082
Khan Sharun, MVSc ⁎ 
, Abhijit M. Pawde, MVSc, PhD
, Abhijit M. Pawde, MVSc, PhD Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
∗Correspondence to: Khan Sharun, MVSc, Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, IndiaDivision of SurgeryICAR-Indian Veterinary Research Institute, IzatnagarBareillyUttar PradeshIndia
El texto completo de este artículo está disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 84 - N° 1
P. e43-e44 - janvier 2021 Regresar al número
Artículo precedente
- Preoperative management of blood thinning agents during cutaneous surgery: The need for an individualized approach
- Sareena Gajebasia, Ron Kerr, Andrew Affleck
- Response to: “Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma”
- Lu Yin, Katerina Svigos, Kumar Sukhdeo, Anthony Ho, Kristen Lo Sicco, Jerry Shapiro
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?